Man Group
RVNC

Man Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Man Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-443,544
Closed -$1.35M – 2429
2024
Q4 		$1.35M Buy
443,544
+143,544
+48% +$625K ﹤0.01% 1416
2024
Q3 		$1.56M Buy
+300,000
New +$1.49M ﹤0.01% 1385
2023
Q3 		– Hold
0
– – – 1668
2023
Q1 		– Hold
0
– – – 627
2021
Q3 		– Sell
-16,600
Closed -$492K – 2141
2021
Q2 		$492K Buy
+16,600
New +$479K ﹤0.01% 1564
2018
Q3 		– Sell
-44,500
Closed -$1.22M – 2250
2018
Q2 		$1.22M Sell
44,500
-100
-0.2% -$3.01K 0.01% 1547
2018
Q1 		$1.37M Buy
+44,600
New +$1.44M 0.01% 1413

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Man Group's RVNC Position: Q1 2025 in Review

Man Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 443,544 shares — an estimated $1.35M sold.

Man Group first reported a position in RVNC in Q1 2018 and held it in 5 quarters. The position peaked at $1.56M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Man Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 443,544 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.35M.
  • Man Group first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
  • Man Group's Revance Therapeutics, Inc. position peaked at $1.56M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.